Prostate cancer screening

No screening test has been proven to reduce prostate cancer mortality. DRE has been the traditional method of screening, and it is often used to detect other diseases in addition to prostate cancer. Newer modalities, such as TRUS and PSA, can identify patients with nonpalpable prostate cancer, but t...

Full description

Saved in:
Bibliographic Details
Published inPrimary care Vol. 19; no. 3; p. 637
Main Authors Roetzheim, R G, Herold, A H
Format Journal Article
LanguageEnglish
Published United States 01.09.1992
Subjects
Biomarkers, Tumor - blood
Cost-Benefit Analysis
Humans
Male
Mass Screening - economics
Mass Screening - methods
Neoplasm Staging
Physical Examination
Predictive Value of Tests
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - epidemiology
Prostatic Neoplasms - pathology
Prostatic Neoplasms - prevention & control
Rectum
Online AccessGet more information

Cover

More Information
Summary:No screening test has been proven to reduce prostate cancer mortality. DRE has been the traditional method of screening, and it is often used to detect other diseases in addition to prostate cancer. Newer modalities, such as TRUS and PSA, can identify patients with nonpalpable prostate cancer, but the use of these tests will also result in many false-positives. In addition, it is not known whether the use of these tests will reduce prostate cancer mortality, or instead cause harm to those patients screened. Given the potential for harm, and the extraordinary expense, routine screening of asymptomatic men with newer modalities should be considered experimental.
ISSN:0095-4543
DOI:10.1016/S0095-4543(21)00943-X